Sign in
TerminatedNo phase

Retrospective Analysis of 68Ga-PSMA-PET in Patients With Prostate Cancer: Experience From Brazil

Key facts

Who runs it
Latin American Cooperative Oncology Group
Where
Brazil3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
12 people enrolled
Started
11 May 2022
Ended
19 Jan 2024
Type of study
Observational
Record updated
21 February 2024
Why it stopped
LACOG and Astellas decided to end the study due to the great difficulty in finding patients with the desired profile.

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age of at least 18 years at study entry
  • Histologically confirmed adenocarcinoma of the prostate
  • 68Ga-PSMA-PET exam performed between October 2015 and January 2021
  • 68Ga-PSMA-PET performed in one of the following situations:; localized disease at diagnosis in patients with no detection of extra-prostatic disease in traditional imaging such as CT scan, MRI and bone scan; biochemical recurrence (according to PCWG3 or defined by the investigator) in patients with no detection of prostatic or extra-prostatic disease in traditional imaging such as CT scan, MRI and bone scan
  • Traditional imaging (pelvic and abdominal CT or MRI and bone scan) with negative results (no extra-prostatic disease, for localized and biochemical recurrence disease; no prostatic for biochemical recurrence disease) performed within 8 weeks before 68Ga-PSMA-PET
  • Site and investigator ability to collect adequate patient characteristics, treatment and outcome data from medical records

Who cannot take part

  • Patients with no disease characteristics accessible in medical records
  • Cancer diagnosis other than prostate cancer in the last 5 years
  • Disease detected by traditional imaging techniques (bone scan, CT and/or MRI), meaning extra-prostatic disease, for localized and biochemical recurrence disease; or prostatic disease for biochemical recurrence disease

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Gallium-68-prostate-specific membrane antigen (68Ga-PSMA) positron emission tomography (PET) has been increasingly used in the management of PCa in Brazil. Thus, the detection of metastatic lesions is improved over traditional methods e.g. MRI and the diagnosis of mCSPC patients has been proportionally increasing. Due to a lack of guidelines and clinical trials including 68Ga-PSMA-PET imaging, the management of these patients is extrapolated from data based on conventional imaging. Treatment decision and duration of treatment for mCSPC patients based on 68Ga-PSMA-PET imaging is currently unknown. 68Ga-PSMA-PET allows a diagnosis of a different set of low volume oligo-metastatic prostate cancer patients. Based on that, a new gap has been built up, since there are no standards of how those patients are managed and how they respond to conventional therapies, to metastasis direct therapy or even if they could be spared of any treatment, reducing costs and toxicities. This patient population has not been included in clinical trials and its critical to generate information on the diagnosis, treatment and outcome of these patients in clinical practice.

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
21 February 2024